25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Fast Facts - United States - U.S. antitrust enforcement agencies concluded 20 “significant invest...
Read More >
Things That 401(k) Plan Sponsors Are Supposed To Do, But Aren't Doing Anyway. So many things they s...
Read More >
On November 21, 2019, the U.S. House of Representatives passed House Resolution (HR) 1309, the Workp...
Read More >
In This Issue. The U.S. House of Representatives voted to approve the SAFE Banking Act, which would ...
Read More >
In this presentation, we will discuss SPACs and recent transactions. The presenters will discuss con...
Read More >
The 2019 novel coronavirus and the disease it causes (“COVID-19”) is changing the landscape of con...
Read More >